Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

Overview

RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to graft-versus-host disease. It may also help doctors predict how patients will respond to a donor bone marrow transplant. PURPOSE: This laboratory study is looking at early detection of graft-versus-host disease in patients undergoing a donor bone marrow transplant.

Full Title of Study: “Using the Transcriptome for Early Detection of Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2012

Detailed Description

OBJECTIVES: Primary – Identify detectable changes in the transcriptomic or proteomic expression prior to clinical manifestations of graft-versus-host disease (GVHD) in blood samples from at-risk patients who have undergone allogeneic bone marrow transplantation. Secondary – Characterize changes in the transcriptome or proteome expression pattern which are predictive of clinically significant GVHD in these patients. – Develop reliable tests which enable early intervention for these patients. OUTLINE: Blood samples are collected prior to and just after typical onset of clinical graft-vs-host disease (GVHD) on days 1, 7-10, 20-23, 30-33, and 60 after allogeneic bone marrow transplantation. RNA is quantified and assessed by microarray analysis to identify changes to transcriptome or proteome expression and markers predictive of the onset of clinical GVHD. Samples are also stored for future analysis.

Clinical Trial Outcome Measures

Primary Measures

  • Identification of changes in the transcriptome or proteome expression prior to clinical manifestations of graft-versus-host disease (GVHD) in patient blood samples
    • Time Frame: Patients beyond period of risk for developing acute GVHD
    • Once a minimum of 20 patients have been enrolled and clinically are beyond their period of risk of developing acute GVHD, samples from at least 5 patients who have developed acute GVHD are compared to samples from at least 5 patients who have had no detectable clinical GVHD. If no differences are detected, additional patients/samples will be enrolled/analyzed.

Secondary Measures

  • Characterization of changes in the expression patterns which are predictive of clinically significant GVHD
    • Time Frame: Patient beyond period of risk for developing acute GVHD
  • Development of reliable tests to predict GVHD in time for early intervention
    • Time Frame: Patient beyond period of risk for developing acute GVHD

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Any patient undergoing an allogeneic bone marrow transplantation at one of the participating Mayo Clinic sites PATIENT CHARACTERISTICS: – Body weight ≥ 15 kg – Not pregnant – Not a prisoner PRIOR CONCURRENT THERAPY: – See Disease Characteristics

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mayo Clinic
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Roberta H. Adams, M.D., Mayo Clinic Cancer Center
  • Overall Official(s)
    • Roberta Adams, MD, Principal Investigator, Mayo Clinic Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.